FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and is antibodies to the Dengue virus.
EFFECT: invention allows obtaining a therapeutic agent based on antibodies to the Dengue virus that do not increase the risk of antibody-dependent infection intensification.
7 cl, 28 dwg, 4 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO DENGUE VIRUS WITH CROSS-REACTIVITY WITH ZIKA VIRUS | 2019 |
|
RU2811697C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
| ANTI-TAU PROTEIN ANTIBODIES AND METHODS OF USING SAID ANTIBODIES | 2016 |
|
RU2732122C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC-REGION VARIANTS, AND THEIR APPLICATION METHODS | 2016 |
|
RU2789884C2 |
| C5 ANTIBODIES AND THEIR APPLICATION METHODS | 2015 |
|
RU2746356C2 |
| ANTIBODIES TO MYOSTATIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2778945C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC REGION VARIANTS AND METHODS OF THEIR USE | 2015 |
|
RU2799522C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
